Anti-tumor Necrosis Factor-α Therapy May Not Be Safe During Pregnancy in Women with Inflammatory Bowel Disease: an Updated Meta-analysis and Systematic Review

Overview

Journal BMC Pregnancy Childbirth

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2024 Apr 8

PMID 38589784

Authors

Wei Huang

Xinxing Zhang

Li Zhang

Xiaosong Dai

Heping Chen

Qin Xie

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory Bowel Disease (IBD) affects reproductive-aged women. Active disease can lead to decreased fertility. Although the vast majority of international guidelines recommend for the continuation of anti-TNF-α during pregnancy, recent studies have raised concerns about the safety of anti-tumor necrosis factor-α (TNF-α) therapy during pregnancy, both for patients and for physicians.

Methods: Studies that evaluate the safety of anti-TNF-α therapy in pregnant women with IBD were identified using bibliographical searches. An updated meta-analysis was performed for pregnancy outcomes, such as live birth, abortion, still birth, preterm birth, low birth weight, congenital abnormalities, and neonatal infection. Odds ratio (OR) with 95% confidence interval (CI) are reported. Data on disease activity, timing of anti-TNF-α therapy were collected for further analysis.

Results: Overall, 11 studies were screened from on-line databases and international meeting abstracts. An increased risk of abortion (OR, 1.33; 95% CI, 1.02-1.74; P = 0.04) and preterm birth (OR, 1.16; 95% CI, 1.05-1.28; P = 0.004), and a decreased risk of live birth (OR, 0.83; 95% CI, 0.74-0.94; P = 0.002]) were found in the anti-TNF-α therapy group compared with the control group (no use of anti-TNF-α therapy). The subgroup analyses based on the disease activity showed there is no significant association between the use of anti-TNF-α therapy during pregnancy on adverse pregnancy outcomes of abortion, preterm birth, and live birth. The rates of still birth, low birth weight, and congenital abnormalities in the anti-TNF-α therapy group were not significantly different from those in the control group.

Conclusions: Anti-TNF-α therapy does not increase the risks of still birth, low birth weight, and congenital abnormalities; however it may be assicated with increased risks of abortion and preterm birth, which are accompanied by a lower rate of live birth. Although these findings may be confounding by potential disease activity, they offer some opposite viewpoints with biologic agent use. Therefore, more studies are required to further confirm the safety of anti-TNF-α therapy in pregnancy with IBD.

References

Haider S, Knofler M . Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2008; 30(2):111-23. PMC: 2974215. DOI: 10.1016/j.placenta.2008.10.012. View

Moens A, van der Woude C, Julsgaard M, Humblet E, Sheridan J, Baumgart D . Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2019; 51(1):129-138. DOI: 10.1111/apt.15539. View

Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T . Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018; 113(11):1669-1677. DOI: 10.1038/s41395-018-0176-7. View

Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G . Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011; 17(9):1846-54. DOI: 10.1002/ibd.21583. View

Seirafi M, De Vroey B, Amiot A, Seksik P, Roblin X, Allez M . Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 40(4):363-73. DOI: 10.1111/apt.12833. View

Mahadevan U, Long M, Kane S, Roy A, Dubinsky M, Sands B . Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2020; 160(4):1131-1139. PMC: 7956164. DOI: 10.1053/j.gastro.2020.11.038. View

Zelinkova Z, van der Ent C, Bruin K, van Baalen O, Vermeulen H, Smalbraak H . Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2012; 11(3):318-21. DOI: 10.1016/j.cgh.2012.10.024. View

Nguyen G, Seow C, Maxwell C, Huang V, Leung Y, Jones J . The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2015; 150(3):734-757.e1. DOI: 10.1053/j.gastro.2015.12.003. View

Marri S, Ahn C, Buchman A . Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13(5):591-9. DOI: 10.1002/ibd.20082. View

10.

Shihab Z, Yeomans N, De Cruz P . Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis. J Crohns Colitis. 2016; 10(8):979-88. DOI: 10.1093/ecco-jcc/jjv234. View

11.

Ekbom A, HELMICK C, Zack M, Adami H . The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991; 100(2):350-8. DOI: 10.1016/0016-5085(91)90202-v. View

12.

Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A . Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2013; 43:78-84. DOI: 10.1016/j.reprotox.2013.11.004. View

13.

Laube R, Selinger C, Seow C, Christensen B, Flanagan E, Kennedy D . Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut. 2023; 72(6):1040-1053. DOI: 10.1136/gutjnl-2022-329304. View

14.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

15.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

16.

Lichtenstein G, Feagan B, Mahadevan U, Salzberg B, Langholff W, Morgan J . Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018; 113(11):1678-1688. DOI: 10.1038/s41395-018-0202-9. View

17.

Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B . Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015; 80(4):727-39. PMC: 4594709. DOI: 10.1111/bcp.12642. View

18.

Esteve-Sole A, Deya-Martinez A, Teixido I, Ricart E, Gompertz M, Torradeflot M . Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy. Front Immunol. 2017; 8:1123. PMC: 5613099. DOI: 10.3389/fimmu.2017.01123. View

19.

Kim M, Kim Y, Chun J, Lee H, Park S, Cheon J . The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Crohns Colitis. 2020; 15(5):719-732. DOI: 10.1093/ecco-jcc/jjaa225. View

20.

Mahadevan U, Cucchiara S, Hyams J, Steinwurz F, Nuti F, Travis S . The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2010; 106(2):214-23. DOI: 10.1038/ajg.2010.464. View